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a b s t r a c t
Inmammals, the peroxisome proliferator-activated receptor (PPAR) plays a key role in regulating var-
ious genes involved in lipid metabolism, bile acid synthesis and cholesterol homeostasis, and is activated
by a diverse group of compounds collectively termed peroxisome proliferators (PPs). Speciﬁc PPs have
been detected in the aquatic environment; however little is known on their pharmacological activity in
ﬁsh.We investigated the bioavailability and persistence of the human PPAR ligand cloﬁbric acid (CFA) in
carp, togetherwith various relevant endpoints, at a concentration similar to therapeutic levels in humans
(20mg/L) and for an environmentally relevant concentration (4g/L). Exposure to pharmacologically-
relevant concentrations of CFA resulted in increased transcript levels of a number of known PPAR
target genes together with increased acyl-coA oxidase (Acox1) activity, supporting stimulation of lipid
metabolism pathways in carp which are known to be similarly activated in mammals. Although Cu,Zn-
superoxide dismutase (Sod1) activity was not affected, mRNA levels of several biotransformation genes
were also increased, paralleling previous reports in mammals and indicating a potential role in hepatic
detoxiﬁcation for PPAR in carp. Importantly, transcription of some of these genes (and Acox1 activity)
were affected at exposure concentrations comparable with those reported in efﬂuent discharges. Collec-
tively, these data suggest that CFA is pharmacologically active in carp and has the potential to invoke
PPAR-related responses in ﬁsh exposed in the environment, particularly considering that CFA may
represent just one of a number of PPAR-active compounds present to which wild ﬁsh may be exposed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are tran-
scription factors activated endogenously by fatty acids and their
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derivatives and are well studied in mammals due to their potential
as therapeutic targets for dyslipidaemia, obesity and diabetes.
There are three known PPAR subtypes, , - and -, which
have different roles in lipid and energy dynamics, show differen-
tial expression patterns and they have different downstream gene
targets. PPAR plays a role in clearance of circulating lipids via reg-
ulation of the expression of genes involved in lipid metabolism,
PPAR is involved in lipid oxidation and cell proliferation, and
PPAR promotes adipocyte differentiation to enhance blood glu-
cose uptake (Singh et al., 2011).
Inmammals, PPARmediates the actionof a structurallydiverse
group of compounds known as peroxisome proliferators (PPs). PPs
bind to the PPAR which in turn binds response elements (PPREs)
in thepromoter regionof target genes that includevarious enzymes
involved in lipid metabolism (Staels et al., 1998). Of these, the most
notable is acyl-coA oxidase (Acox1), which has an important role in
http://dx.doi.org/10.1016/j.aquatox.2015.01.033
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peroxisomal ˇ oxidation. Others include enzymes involved in other
stages of fatty acid catabolism via both peroxisomal and mitochon-
drial -oxidation pathways (including several cytochrome P450
(CYP) 4 isoforms), lipoprotein metabolism, triglyceride clearance
(e.g., lipoprotein lipase) and cholesterol catabolism (CYP7A1 and
CYP27A). PPREs have also been identiﬁed in the promoter regions
of a number of genes involved in inﬂammation, gluconeogene-
sis, biotransformation, ketogenesis, lipogenesis, and amino acid
metabolism (Mandard et al., 2004). In some species, PPs cause
peroxisome proliferation and have been associated with oxidative
stress and hepatocarcinogenesis resulting from an increased pro-
ductionofhydrogenperoxide (H2O2) (RaoandReddy,1991). PPAR
is targeted therapeutically in humans by ﬁbrate drugs, which are
used clinically to lowerbloodplasma lipid levels, via transcriptional
activation of a number of genes regulated by PPAR (Staels et al.,
1998).Aswithmanyof theorphannuclear receptors, PPARhasbeen
well conserved during vertebrate evolution. Fish have three iso-
forms analogous to mammalian PPAR, - and - (Andersen et al.,
2000; Maglich et al., 2003; Boukouvala et al., 2004; Leaver et al.,
2005) which in some species are present as multiple isoforms of
individual subtypes (Leaver et al., 2005) due to evolutionary gene
duplication events (Urbatzka et al., 2013). In commonwith rodents,
high levels of expression of PPAR has been reported in the liver
of several ﬁsh species (Ibabe et al., 2002; Ibabe et al., 2004; Leaver
et al., 2007; He et al., 2012) probably due to the organ’s prominent
role in fatty acid oxidation (Colliar et al., 2011).
A wide range of chemicals discharged into the environment
are known to interact with PPAR, including certain pharmaceu-
ticals (e.g., the ﬁbrates), phthalate ester plasticizers, PAHs, PCBs,
alkylphenols, and some pesticides (Gibson, 1993). Complex efﬂu-
ent discharges from bleached kraft pulp and paper mills have also
been shown to induce peroxisome proliferation in ﬁsh and other
aquatic species (Cajaraville et al., 2003). Despite this, there are rel-
atively few published data on the activity of PPs in ﬁsh, especially
with respect to downstream effects on genes important in hepatic
metabolism and detoxiﬁcation.
In vitro reporter gene assays have previously shown that
hypolipidemic drugs are agonists of teleost (rainbow trout, in par-
ticular) PPARs (Liu et al., 2005) and consequently, we investigated
responses in the PPAR system in carp (Cyprinus carpio) exposed,
in vivo, to cloﬁbric acid (2-(4)-chlorophenoxy-2-methyl propionic
acid; CFA) the active metabolite of the lipid lowering ﬁbrate cloﬁ-
brate. First marketed in the US in 1967, cloﬁbrate was widely
prescribed in humans and is still commonly detected in the aquatic
environment at concentrations ranging from high ng/L to lowg/L
in sewage efﬂuents and surface waters (Stan and Linkerhagner,
1992; Stan et al., 1994; Heberer et al., 1995; Buser et al., 1998;
Ternes, 1998; Tixier et al., 2003; Zorita et al., 2008). CFA has also
been detected in groundwater and drinking water at levels up to
4g/L and 270ng/L, respectively, (Heberer and Stan, 1997) illus-
trating that it is highly mobile and persists in the environment.
Indeed, CFA is regarded as a relatively persistent drug residue with
an estimated lifespan in the environment of 21 years (Buser et al.,
1998; Zuccato et al., 2000; Winkler et al., 2001; Tixier et al., 2003).
In this study, two exposure concentrations of CFA were selected
for studies into the effects of this drug in ﬁsh, speciﬁcally the carp,
C. carpio. The ﬁrst concentration (20mg/L in the exposure water)
was chosen in an attempt to generate a pharmacologically-relevant
concentration in the exposedﬁshwhichbasedonprevious data and
reported human therapeutic plasma concentrations is between 50
and250g/mL (Regenthal et al., 1999). This concentrationwascho-
sen to examine the potential for mode of action-related effects, in
a non-target, environmentally-relevant species. The second con-
centration employed (4g/L) was selected to establish whether
such effects occurring for therapeutic doses could occur at an expo-
sure level comparable with measured concentrations of CFA in the
aquatic environment. For each treatment three sampling points
were employed, each incorporating the measurement of plasma
CFA levels to assess bioavailability and propensity for persistence
in carp.
Transcriptional responses toCFAexposure in carpwereassessed
via temporal changes in mRNA levels of hepatic ppara and
target genes known to be regulated via PPAR in mammals.
These included genes encoding acyl-coA oxidase (acox1), thiolase
(acaa1) and cytochrome P450 4 (cyp4) which are involved in lipid
metabolism; sterol 27-hydroxylase (cyp27a) and apolipoprotein-
A1 (apoa1)whichplaya role incholesterolhomeostasis; lipoprotein
lipase (lpl) involved in lipoprotein metabolism; and Cu/Zn super-
oxide dismutase (sod1) a cellular antioxidant. Acyl-coA oxidase
(Acox1) activity, and Cu,Zn superoxide dismutase (Sod1), a key
antioxidant enzyme controlled via the PPAR in mammals, were
also measured. The in vivomRNA levels of several key genes encod-
ing proteins involved in hepatic drug metabolism (cyp2k, cyp3a,
gsta, gstp) and transport (mdr1, mrp2) were also measured as we
have shown previously that these are responsive to CFA in cultured
carp hepatocytes. The liver was the main target tissue for studies
on gene responses in the PPAR pathways due to its role in fatty
acid metabolism.
2. Materials and methods
2.1. Animals and test chemicals
Juvenile common carp (C. carpio) of approximately 6 months
old, with mean weight of 2.5±0.48g (mean± SEM, n=360) and
mean fork length of 49±4.3mm (mean± SEM) were held in aer-
ated tanks in a ﬂow-through water system, at 22 ◦C, maintained
under a 16:8 light:dark cycle and fed daily ad libitum with pel-
leted feed (Biomar Incio Plus 0.8mm). Fish were supplied by the
husbandry unit at AstraZeneca, Brixham and were acclimated for
8 weeks prior to being transferred into experimental tanks at the
start of the exposure experiment.
Test compounds were all obtained from Sigma–Aldrich, Poole,
UK, unless stated otherwise.
2.2. Experimental design
Carp were exposed to CFA (CAS: 882-09-7) via a ﬂow through
system. On day zero, carp were randomly allocated to one of three
duplicated treatment groups; 20mg/L CFA, 4g/L CFA or dilution
water controls; in 9 L glass tanks at a density of 10 ﬁsh per tank.
There were 3 sampling time points, giving a total of 6 tanks per
treatment. Two separate stock solutions were prepared for the
two dosing regimens. For the high (pharmacological) concentra-
tion exposure (20mg/L), a 2.5 g CFA/L stock solution was prepared
in reverse osmosis (RO) water using 0.6 g/L NaOH in order to assist
dissolution. For the 4g/L concentration exposure, a 2.5mg CFA/L
stock was prepared from the ﬁrst solution. These stock solutions
were diluted in dechlorinated tap water and delivered to each
mixing cell at appropriate ﬂow rates to give the desired nominal
concentrations of 20mg/L and 4g/L, respectively. The CFA solu-
tions were delivered to the individual tanks at a rate of 60mL/min.
To balance the concentration of NaOH across all treatments, a stock
of RO water containing NaOH [0.6 g/L] was also delivered to the
dilution water control (containing only dechlorinated tap water)
and 4g/L treatments. The stock solutions were replaced every
two days. Water was maintained at 22±0.2 ◦C (mean± SEM), with
water temperature, dissolved oxygen and pH measured in all tanks
at least twice weekly during the exposure period (Table 2).
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2.3. Sampling
Duplicate tanks of ﬁsh were sampled at day 4 and day 10 of
the exposure. The remaining ﬁsh were then depurated for a further
4 days (exposed to dilution water only) and sampled on day 14.
On each sampling day, 20 ﬁsh (10 from each replicate tank) were
sampled from each treatment group. Fish were anaesthetized in
MS222 solution (500mg/L in dechlorinated water, adjusted with
1g/L NaHCO3 to pH 7.3), weighed, fork length measured and blood
collected from the caudal vein using heparinized (5000U/mL) cap-
illary tubes. Blood was centrifuged immediately (7000× g, 4min;
Haematokrit 210, Hettich) and plasma separated, snap frozen and
stored at −80 ◦C until further analysis. Fish were then humanely
killed according to UK Home Ofﬁce regulations, and the liver
dissected out, weighed, snap frozen and stored at −80 ◦C until
required.
2.4. Water and plasma analysis
CFA was measured in water samples from each individual tank,
and in the plasma isolated from each sampled ﬁsh, using liq-
uid chromatographywith tandemmass spectrometry (LC–MS/MS).
Water andplasma sampleswere prepared using acetonitrile and an
internal standard added prior to analysis.
2.4.1. Sample preparation: water samples
For dilution water control and low dose (4g CFA/L) samples,
800L of each water sample was transferred to a 96 deep well
plate. 200L of acetonitrile, containing 50nM of internal stan-
dard was added prior to analysis by LC–MS/MS. For high dose
(20mg CFA/L) samples 50L of each water sample was transferred
to a vial containing 10mL of 10nM internal standard in 80:20
water:acetonitrile. 1mL was then transferred to a 96 deep well
plate for analysis by LC–MS/MS.
2.4.2. Sample preparation: plasma samples
10L plasma from individual ﬁsh in the highdose (20mgCFA/L)
samples, or 50L plasma (pooled from ﬁve ﬁsh) for dilution water
control and lowdose (4g CFA/L) sampleswere added to a 96 deep
well plate along with 490L acetonitrile and the sample extracted
using a Genogrinder (Spex) at 1000 stokes/min for 3min. The plate
was centrifuged at 4000 rpm for 30min and 200L of supernatant
removed and evaporated to dryness (Turbovap). The residue was
re-suspended in 80:20 water: acetonitrile; 200L for the low dose
and dilution water control samples and 400L for the high dose
samples (equivalent to ×10 or ×100 dilution, respectively); con-
taining 10nM internal standard, ready for analysis by LC–MS/MS.
2.4.3. Instrumental analysis
LC–MS/MS analyzes were performed using a CTC PAL autosam-
pler (Thermo) with a MS gradient pump (Thermo) interfaced
to a TSQ Quantum Access triple quadrupole mass spectrometer
(Thermo) equipped with a heated ESI probe. Chromatographic
separation was achieved using a Hypersil Gold C18 col-
umn (50×2.1mm, 3M (Thermo) running gradient elution at
500L/min. Eluents were: (A) water and (B) methanol, both con-
taining 0.1% of formic acid. Gradient elutionwas applied as follows:
For water samples, 0min 20% B; 1.5min 100% B; 3min 100% B
and 3.01min 20% B and for plasma samples, 0min 20% B; 1.5min
20% B; 10min 100% B; 12.5min 100% and 12.51min 20% B. For
water samples, retention time of CFA and the internal standard
was 1.9min and 1.6min, respectively, while for plasma sam-
ples they were 6.4min and 5.5min. The mass spectrometer was
operated in negative ion, electrospray ionization mode using the
following parameters: Capillary temperature – 270 ◦C; vaporizer
temperature –350 ◦C; spray voltage –2850V; sheath gas –nitrogen
at 50 (arbitrary units) and auxilary gas – nitrogen at 30 (arbitrary
units).
Compound detection was by selected reaction monitoring
(SRM) using argon at 1.5 torre as a collision gas and the following
transitions monitored; For CFA, the precursor ion was the deproto-
nated molecular ion m/z=213 and the product ion was m/z=127 at
a collision energy of 18V. For the internal standard, the precursor
ion was the deprotonated molecular ion m/z=406 and the product
ion was m/z=172 at a collision energy of 31V. Quantitation was by
peak area with reference to standards of known concentration of
CFA using an internal standard method.
2.5. mRNA analyzes
2.5.1. RNA extraction and reverse transcription
Frozen 10mg aliquots of liverwere homogenized directly in Tri-
reagent (Chomczynski, 1993) and total RNA was isolated following
manufacturer’s instructions. The amount of RNA was quantiﬁed
using a NanoDrop spectrophotometer and RNA quality was deter-
mined both by electrophoresis on an ethidium bromide-stained
1.5% agarose gel and through themeasurement of A260/A280 ratio.
1g RQ1 DNase treated (Promega) total RNA was subsequently
reverse transcribed to cDNA using random hexamers (Euroﬁns
MWGOperon) andMMLV reverse transcriptase (Promega), accord-
ing to the protocol described previously (Filby and Tyler, 2005).
2.5.2. Real-time quantitative polymerase chain reaction
(RT-qPCR)
RT-qPCR was carried out on cDNA samples for each of the
treatments at each of the three sampling points (N=8 for each
treatment) for the target genes using Absolute QPCR SYBR Green
Fluorescein mix (ABgene) according to the protocol described pre-
viously (Filby and Tyler, 2005). Brieﬂy, primer pairswere optimized
for annealing temperature (Ta), speciﬁcity conﬁrmed bymelt curve
analysis, and the detection range, linearity and ampliﬁcation efﬁ-
ciency (E) established using serial dilutions of carp liver cDNA.
RT-qPCR was carried out using Absolute QPCR SYBR Green Fluores-
ceinmix (ABgene), with an initial activation step of 95 ◦C for 15min
followed by 30–40 cycles of denaturation (95 ◦C, 10 s) and anneal-
ing (appropriate Ta, 45 s) and ﬁnal melt curve analysis. Ribosomal
protein 8 (rpl8) was used as a ‘housekeeping’ gene, to normalize
the target gene expression, using a development of efﬁciency cor-
related relative quantiﬁcation as described previously (Filby and
Tyler, 2005), as it was found not to alter following exposure to CFA
(p>0.05) (Corcoranet al., 2012).Details of primersused forRT-qPCR
are shown in Table 1.
2.6. Biochemical analyzes
2.6.1. Acyl coA-oxidase (Acox1) activity
Acox1 (EC 1.3.3.6) activity was quantiﬁed in liver homogenates
for each sample (N=8 per treatment per sampling point) by ﬂuoro-
metricallymeasuring the production of the reactive oxygen species
(ROS) hydrogen peroxide (H2O2; generated speciﬁcally by the per-
oxisomal-oxidation pathway) using amodiﬁcation of themethod
described previously (Poosch and Yamazaki, 1986). Lauroyl-CoA
was used as the enzymatic substrate and production of H2O2 via
the direct transfer of electrons to oxygen by Acox1 determined by
measurement of the oxidation of 4-hydroxyphenylacetic acid to a
ﬂuorescent product (6,6′-dihydroxy-(1,1′-biphenyl)-3,3′;-diacetic
acid) in a horseradish peroxidase-coupled reaction. 10mg frozen
liver aliquots were homogenized in buffer containing 0.3M manni-
tol, 10mMHEPES,1mMEGTA(pH7.2) inahand-heldhomogenizer.
Homogenates were centrifuged at 3000× g for 5min to remove
unbroken tissue and heavy mitochondria. Assays were performed
in a 96-well plate with 10L of each sample added to wells
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Table 1
Target genes and details of primers and assays used with RT-qPCR analysis. Ta is annealing temperature; PCR efﬁciency represents the ‘E’ value.
Gene Accession number Primer direction Primer sequence (5′–3′) Ta (◦C) E Product size (bp)
Peroxisome proliferator-activated receptor  ppara FJ849065 Sense GGGAAAGAGCAGCACGAG 62.0 2.032 105
Antisense GCGTGCTTTGGCTTTGTT
Acyl coA-oxidase acox1 CF660510 Sense ACAGCACAGCAAGAGCAATG 59.0 1.971 104
Antisense ACAGAGTGGACAGCCGTATC
Thiolase acaa1 Seea Sense TTGCCTGTGGTGTGGAG 59.0 2.200 90
Antisense CAACATTCTCTGAGGTTATTCC
Cytochrome P450 4 cyp4 GU046698 Sense TTGACCTCTGCCACTTG 57.0 2.110 138
Antisense CTGATAACTTCCGCTGTATG
Lipoprotein lipase lpl FJ716101 Sense TTGGGTTACAGTCTTGGTGCTC 62.0 2.110 104
Antisense AAAGGGCATCATCGGGAGAAAG
Apolipoprotein A1 apoa1 AJ308993 Sense GCCGAAGAAGGTGAAGC 57.0 2.012 82
Antisense GGTGGCAAGGAAGAAAGG
Sterol 27 hydroxylase cyp27a CF660988 Sense GAGCCACGAAAGTTCAAACC 56.0 2.012 88
Antisense CATCTCCAGTTCAGCAATGC
Cu,Zn superoxide dismutase sod1 CA964628 Sense GGAATACTCGGTCATTGG 54.0 2.036 100
Antisense ACTGAGTGATGCCTATAAC
Cytochrome P450 2 K cyp2k GU046696 Sense GCTCTTCCTGTTCTTC 60.0 2.070 103
Antisense TGTGACTTCTACTACTC
Cytochrome P450 3 A cyp3a GU046697 Sense CCAAGGACCACAAGAAGAAG 60.0 1.921 159
Antisense AGCCGCCGAAGATGAAG
Glutathione S-transferase  gsta DQ411310 Sense TACAATACTTTCACGCTTTCCC 61.5 1.979 149
Antisense GGCTCAACACCTCCTTCAC
Glutathione S-transferase  gstp DQ411313 Sense GTCCTTTGCTCTGCCTCTCTG 60.5 2.103 141
Antisense TTACTGCTTGCCATTGCCATTG
Multidrug resistance 1 (ATP-binding cassette
sub-family B member 1)
mdr1(abcb1) AY999964 Sense TTGCGGCTGTGGGAAGAG 58.5 2.104 109
Antisense GTGGATGTTCAGTTGCTTTGTG
MDR related protein 2 mrp2(abcb1) AY679169 Sense TTCGGCTCTAATCTGGATG 58.5 2.080 149
Antisense CTCACCCGCTGTTTCTG
Ribosomal protein 8 rpl8 See (Bickley et al., 2009) Sense CTCCGTCTTCAAAGCCCATGT 60.0 2.140 N/A
Antisense TCCTTCACGATCCCCTTGATG
a CarpBase, http://legr.liv.ac.uk/carpbase/index.htm (Williams et al., 2008).
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Fig. 1. mRNA levels of genes associated with PPAR activation in carp exposed via the water to cloﬁbric acid at 20mg/L (dark grey bars) and 4g/L (light gray bars) and to a
dilution water control (white bars). Data are presented as mean fold difference relative to the mean control at the respective time point. Fish were sampled at day 4 and day
10 of the exposure. N=8 for each treatment. Error bars represent SEM. An asterisk above the bar indicates a signiﬁcant difference compared to the control group (p<0.05).
containing 50L of assay cocktail comprised of 60mM potassium
phosphate buffer (pH 7.4) containing 4U/mL horseradish per-
oxidase, 1mM 4-hydroxyphenylacetic acid, 100M lauoryl-CoA,
20M ﬂavin adinine dinucleotide (FAD) and 0.2mg/mL triton X-
100. Samples were added to wells with assay cocktail containing
no substrate as controls. Samples were added under indirect light
as FAD is light sensitive, incubated in the dark at 37 ◦C for 30min
and the reactions terminated by the addition of 1.5mL of chilled
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Table 2
Nominal and measured water concentrations of CFA and pH and oxygen saturation during the 10 day exposure period and subsequent 4 day depuration. Measured
concentrations, oxygen saturation and pH values are given as mean± standard error. There was no depuration period for the 4g/L treatment group.
Nominal water concentration of CFA
Control 4g/L 20mg/L
Measured concn. (mean± SE, n=18) <LOQa 4.61±0.58 18.58±4.51
% Nominal concn. – 115.25 92.90
Measured concn. during depuration <LOQ – <LOQ
pH (mean± SE, n=18) 7.61±0.16 7.51±0.04 7.63±0.01
O2% sat. (mean± SE, n=18) 79.07±0.86 80.54±0.72 79.95±0.75
Measured concentration values are presented in g/L for the 4g/L group and mg/L for the 20mg/L group. aLOQ= limit of quantiﬁcation LOQ=1.3g/L.
100mMsodiumcarbonate buffer (pH10.5) containing 2mMpotas-
sium cyanide. All sampleswere analyzed in triplicate. Fluorescence
was measured at room temperature with excitation at 318nm and
emission at 405nm (Tecan MS200); the difference in ﬂuorescence
with and without lauroyl-coA in assay cocktail was used to indi-
cate Acox1 activity. H2O2 concentrations were determined relative
to a standard curve of known amounts of H2O2 incubatedwith sub-
strate free assay cocktail. H2O2 standardsweremade daily by serial
dilution of 30% H2O2 in deionized water. Protein concentrations in
the cell homogenateswere determined for each sample using Brad-
ford reagent (an assay based on Bradford, 1976) and bovine serum
albumin (Fisher) as reference standard protein. Acox1 activity was
expressed as activity/min/mg protein.
2.6.2. Cu,Zn superoxide dismutase (SOD1) activity
Sod1 (EC 1.15.1.1) activity was measured in liver cytosol for
each sample (N=8 per treatment per sampling point) according
to the protocol described previously (Porte-Visa et al., 2005) based
on inhibition of the reduction of nitro-blue tetrazolium (NBT) by
superoxide, using xanthine as the substrate. Frozen samples of liver
(∼10mg) were homogenized in 1mL PBS (pH 7.4), centrifuged at
14,000× g for 10min and the supernatant (cytosol) separated to
measure SOD1 activity only; SOD1 makes up 90% of cellular SOD
and is present in the cytosol whereas SOD2 is present in the mito-
chondrial fraction. The cytosol fraction was diluted 1:10 in PBS and
25L loaded into a 1mL cuvette with 1.25L xanthine oxidase
and 965L substrate solution containing 0.1mM xanthine, 0.1mM
EDTA, 0.05mg BSA/mL and 0.025mM NBT. The absorbance at a
wavelength of 560nm was then recorded spectrophotometrically
and units of Sod1 activity calculated by comparison to a standard
curve of Sod1 activity using knownconcentrations of Sod1between
0.001and1U/mL. Protein concentrationsweredetermined for each
sample using Bradford reagent (as above) and SOD1 activity was
expressed as units of enzyme activity/min/mg protein.
2.7. Data analysis
Data are presented throughout as mean± standard error of
the mean (SEM). All statistical analyzes were carried out using
SigmaPlot® software (Systat Software, Inc., Chicago, USA). Data
were tested for normality/equality of variances, and log trans-
formed if necessary. Effects of test compounds on levels of gene
expression, enzyme activity, and morphological endpoints were
determined using one-way ANOVA followed by Fisher LSD multi
comparison procedure, where appropriate. This study was not
intendedas a toxicological assessmentof CFA, but ratherwasessen-
tially comprised of two separate experimental paradigms focused
on a pharmacological or environmentally-relevant exposure level,
and thus treatment responses were compared directly with the
relevant control groups.
Where data did not meet the assumptions of normality and/or
homogeneity of variance, datawere analyzed using Kruskal–Wallis
one-way ANOVA on ranks followed by Dunn’s post hoc analysis. In
all cases, p<0.05 was considered statistically signiﬁcant.
3. Results
3.1. CFA concentrations in the exposure water and ﬁsh plasma
During the exposure, mean measured water concentrations of
CFA were 4.61±0.58g/L and 18.58±4.5mg/L (mean± SE, n=18)
for the 4g/L and 20mg/L nominal tanks, respectively (Table 2).
After 4 days of depuration, CFA concentrations in the water were
below the limit of quantiﬁcation (1.3g/L) in all tanks.
Concentrations of CFA measured in the plasma of exposed carp
are summarized in Table 3. In the lower (environmental) expo-
sure treatment (4g/L) and dilution water control groups plasma
levels were below the limit of quantiﬁcation (20g/L) across all
time points measured. In the pharmacological concentration expo-
sure group (20mg/L) after 4 days exposure, the blood plasma
levels of CFAwere 5.54±0.45mg/L (approximately 28%of themea-
sured water levels) and after 10 days exposure there was little, if
any change in this concentration (6.11±0.43mg/L; approximately
30%). After 4 days of depuration, plasma levels were below the
limit of quantiﬁcation (20g/L) in all treatment groups. The mean
recovery from fortiﬁed plasma samples was 103%, with a relative
standard deviation (RSD) of 3.0.
3.2. Morphometric parameters
There was no signiﬁcant effect of CFA concentration on the
size, growth or condition of the ﬁsh at any of the time points
sampled (Table 3). There was also no effect of the treatment on
hepato-somatic index (HSI). Blood hematocrit was signiﬁcantly
elevated in plasma from ﬁsh exposed to the pharmacological
CFA concentration at day 4 (ANOVA, p<0.05) but there were no
signiﬁcant effects at any of the other time points or treatment
levels.
3.3. Hepatic transcript levels of PPAR˛-related genes
Fig. 1 shows transcript levels of a suite of genes known to be
regulated by PPAR in mammals, measured in carp exposed to the
two concentrations of CFA for 4 or 10 days. Levels were also mea-
sured after 4 days depuration; however there was no signiﬁcant
difference in mRNA levels for any of the genes measured across the
treatments at this time point (i.e., no treatment effects; data not
shown).
After 4 days of exposure, ppar˛ transcript levels were signiﬁ-
cantly higher in the ﬁsh exposed to 20mg/L compared with the
control animals (approximately 2.5-times control levels). Acox1
transcript levels were signiﬁcantly higher at both exposure con-
centrations, with mRNA levels reaching almost 4 times higher than
the control levels in the 20mg/L treated ﬁsh. Transcript levels
of cyp4 and lpl were signiﬁcantly higher in the 4g/L exposed
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Table 3
Fish morphometric and physiology data. All data presented as mean± standard error; HSI =hepatic somatic index, calculated as liver weight/ﬁsh wet weight; condition factor
(K) calculated as (ﬁsh wet weight/(fork length3)); Haematocrit calculated after centrifugation of the blood in capillary tubes (see Section 2) and deﬁned as a ratio of red blood
cell (RBC) volume to total blood volume, and expressed as a percentage of total blood volume. LOQ= limit of quantiﬁcation (20g/L).
Nominal water concentration CFA
Control 4g L−1 20mgL−1
Day 4 Day 10 Day 14 Day 4 Day 10 Day 4 Day 10 Day 14
Plasma [CFA] (g/L) <LOQ <LOQ <LOQ <LOQ <LOQ 5537±450 6113±430 <LOQ
Liver weight (g) 0.043±0.01 0.052±0.02 0.053±0.01 0.052±0.01 0.065±0.02 0.048±0.01 0.049± 0.01 0.061±0.01
Fish wet weight (g) 2.40±0.77 2.83±0.67 3.07±0.57 3.14±0.82 3.78±0.82 2.48±0.47 2.924±0.64 3.46±0.54
HSI 1.87±0.29 1.85±0.35 1.83±0.36 1.71±0.33 1.74±0.54 1.98±0.42 1.70 ±0.46 1.77±0.33
Fork length (mm) 48.55±5.32 51.44±3.76 52.99±3.61 53.61±4.92 55.82±3.64 49.24±3.81 52.04±3.87 55.19±3.55
Condition factor (K) 2.04±0.13 2.04±0.13 2.05±0.05 2.01±0.16 2.15±0.13 2.07±0.02 2.05 ± 0.16 2.05±0.14
Haematocrit % (RBC:total blood) 33.49±1.48 35.69±0.74 34.74±1.19 34.53±1.01 35.74±0.89 37.69±0.90* 36.62±0.89 33.00±1.04
* Indicates signiﬁcant difference to control value (p<0.05).
animals only (2.5-times and 3.5-times, respectively), and in
contrast cyp27a mRNA levels were signiﬁcantly reduced, by
approximately twofold in the pharmacological exposure group
relative to controls levels. There was no signiﬁcant change in tran-
script levels of acaa1, apoa1 or sod1 after 4 days of exposure.
After 10 days of exposure acox1, apoa1 and cyp27a transcript
levels were signiﬁcantly higher relative to control at both expo-
sure concentrations (up to 3.5, 2 and 2-times, respectively). Acaa1,
cyp4 and lpl mRNA levels were increased relative to controls at
4g/L only (2.5, 2.5 and 4-fold, respectively) and sod1 transcrip-
tion was higher (by 2-times control) at 20mg/L only. There was
no change in the transcript levels of ppara for either exposure
level.
3.4. Acyl-coA oxidase (Acox1) and Cu,Zn superoxide dismutase
(Sod1) activity
After 4 days of exposure to CFA, Acox1 activity was signiﬁ-
cantly higher (2.5-times higher) in the 20mg/L treated animals
compared with controls and this was also the case in both treat-
ment groups after 10 days (between approximately 2- and 2.5- fold
higher; Fig. 2). Interestingly, even after 4 days of depuration, Acox1
Fig. 2. Activity of acyl-coA oxidase (expressed in pmol peroxisomal H2O2 produc-
tion per minute per mg protein) in carp exposed via the water to cloﬁbric acid at
20mg/L (dark grey boxes) and 4g/L (light grey boxes) and to a dilution water con-
trol (white boxes) after 4 and 10 days exposure and a further 4 days depuration
(day 14). There were no depuration data for 4g/L treatment. Activity is expressed
as pmol H2O2 per minute per mg protein as described in methods.N=8 in each case.
Box represents inter-quartile range, bars represent maximum and minimum values
and horizontal line represents median value for each treatment. Asterisks above
boxes indicate signiﬁcant differences compared with the control group (*p<0.05,
**p<0.001).
activity remained signiﬁcantly higher (approximately 2-times) in
the 20mg/L treated animals relative to controls.
There was no signiﬁcant effect of CFA treatment on Sod1 activ-
ity at any sampling point during the exposure or depuration
(Fig. 3).
3.5. Transcript levels of genes with products involved in hepatic
biotransformation
After 4daysof exposure toCFA, all of the analyzeddrugbiotrans-
formation and transport genes (cyp2k, cyp3a, gstp, mdr1, mrp2),
except for gsta, showed signiﬁcantly higher transcript levels com-
pared with controls at one or both treatment levels (Fig. 4). The
patterns shown differed between genes, however: cyp2k and mrp2
mRNA levels were signiﬁcantly higher at 20mg/L (by 1.9 and 2.7
times, respectively); whereas cyp3a, gstp and mdr1 mRNA levels
were elevated only at 4g/L (1.4, 5 and 5-times, respectively).
There was no effect on the transcription of gsta after 4 days of
exposure.
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Fig. 3. Enzyme activity of Cu,Zn superoxide dismutase (SOD1) in livers of carp
exposed to CFA [20mg/L (dark grey bars), 4g/L (light gray bars) and dilution water
controls (white bars) after 4 and 10 days exposure and after 4 days depuration (day
14). SOD1wasmeasuredvia inhibitionof the reductionofNBTandexpressedasunits
of SOD1 activity per minute per mg protein. One unit of SOD activity was deﬁned as
the amount of enzyme resulting in 50% inhibition of NBT reduction as calculated by
use of a standard curve with known amounts of SOD. Error bars represent standard
error. N=3 for each treatment. There was no low concentration exposure group for
day 14. There were no signiﬁcant differences between time points.
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Fig. 4. mRNA levels of genes involved in xenobiotic metabolism in carp exposed via the water to cloﬁbric acid at 20mg/L (dark grey bars) and 4g/L (light grey bars) and to a
dilution water control (white bars). Data are presented as mean fold difference relative to the mean control at the respective time point. Fish were sampled at day 4 and day
10 of the exposure. N=8 for each treatment. Error bars represent SEM. An asterisk above the bar indicates a signiﬁcant difference compared to the control group (p<0.05).
After 10 days of exposure to CFA, transcript levels of all hep-
atic biotransformation genes were signiﬁcantly elevated at one or
both treatment levels compared with the respective control, with
the exception of mdr1. Conversely, mdr1 mRNA levels were signif-
icantly lower (3 times) than the controls at 20mg/L CFA.
Most gene transcripts showed signiﬁcantly higher levels at both
4g/L and 20mg/Lwith the exception of cyp3awhichwas elevated
only at 4g/L (1.8 times relative to control). The greatest changes
observed were for gsta and mrp2 mRNA where in the 4g/L expo-
sure group transcription was 4.3 and 4.6 times those of control
levels, respectively.
No signiﬁcant difference in transcript levels occurred across any
of the genes measured after 4 days of depuration (data not shown).
4. Discussion
In mammals, PPAR activation results in modiﬁed transcript
levels of various genes associated with the inducible -oxidation
pathway in peroxisomes (and to a lesser extent in mitochondria).
These include the key genes acyl-coA oxidase (acox1), enoyl-
coenzyme A hydratase/3-hydroxyacyl coenzyme A dehydrogenase
(ehhadh), and thiolase (acaa1), as well as fatty acid transport pro-
tein (fatp1) and long-chain acyl-coA synthetase (acs). In mammals,
upregulationof these genes collectively serves to increase fatty acid
uptake, conversion and oxidation in the liver, resulting in a lower
availability of fatty acids for triglyceride synthesis (Staels et al.,
1998).
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In ﬁsh, less is known of the function of PPARs (Ibabe et al.,
2004), althoughbothPPAR andPPARhavebeen shown toexhibit
activation proﬁles to a range of ligands known to activate themam-
malian counterparts (Cocci et al., 2013), and a comparable role in
lipid regulation is likely fromthedatagenerated thus far (Prindiville
et al., 2011; Venkatachalam et al., 2012). Here we exposed carp to
two concentrations of the PPAR ligand CFA: 20mg/L and 4g/L
which were, respectively, selected to investigate the responsive-
ness of carp to PPAR activation at a pharmacologically-relevant
concentration, and to assess whether such activation could occur
at CFA concentrations similar to those previously measured in the
environment.
Acox1 induction, in particular, is a key, rate-limiting step in the
peroxisomal -oxidation pathway in mammals, and is also sug-
gested to be a rapid and speciﬁc marker of exposure of aquatic
organisms to PPs (Cajaraville et al., 2003). We found transcript
levels ofacox1, and toa lesser extentacaa1,were increasedonexpo-
sure of carp to CFA supporting activation of the PPAR pathway,
at the concentration of 4g CFA/L comparable with levels mea-
sured in efﬂuents discharged into the environment. Furthermore,
elevated levels of acox1 mRNA coincided with increased Acox1
enzyme activity, in agreement with previous studies on other
ﬁsh species, including increased acox1 mRNA levels in zebraﬁsh
(Venkatachalamet al., 2012) and elevatedAcox1 enzyme activity in
both fatheadminnow(Westonet al., 2009) and salmonhepatocytes
(Ruyter et al., 1997) after exposure to CFA.
In humans, several members of the cytochrome P450 4 (CYP4)
family are known to be transcriptionally regulated by PPAR. These
enzymeshave an important role inmicrosomal-oxidation of fatty
acids (Hardwick, 2008) and there is a close association between
induction of CYP4 and activation of the peroxisomal fatty acid
metabolizing system (Simpson, 1997). In ﬁsh, a link between CYP4
and PPAR has not been established. In the present study, the
effects of CFA on cyp4mRNA levels are not easily explained as there
was an apparent increase in expression upon CFA exposure at the
lower exposure concentration, but not at the higher exposure. In
a previous study in Fundulus heteroclitus, exposure to 10g CFA/L
did not result in alteration of CYP4A protein levels after 17 days of
exposure (Emblidge and DeLorenzo, 2006).
In line with the induction of hepatic peroxisomal -oxidation
in rodents (but not in humans) it is well documented that PPs,
including ﬁbrates, increase peroxisomal number and volume (per-
oxisome proliferation) which can in turn result in oxidative stress
and in some cases hepatocarcinogenesis (Rao and Reddy, 1991). In
rainbow trout hepatocytes in vitro, it has been shown that CFA and
the related ﬁbrate ciproﬁbrate, but not gemﬁbrozil, increase the
activity of peroxisomal Acox1 and that there is a strong correla-
tion between induction of Acox1 activity and the relative amount
of peroxisomal bifunctional enzyme after exposure to any of these
three compounds (Donohue et al., 1993). Similarly, in vivo expo-
sures of rainbow trout to the lipid regulating drugs ciproﬁbrate
or gemﬁbrozil resulted in an increase in Acox1 enzyme activity
and induction of oxidative stress (Yang et al., 1990), or an increase
in liver/body weight ratio (Scarano et al., 1994), respectively.
Although peroxisomal parameters were not measured directly
here, the absence of changes in HSI here suggests increased liver
volume in carp is not signiﬁcant following exposure to CFA. The
resultant oxidative stress associated with peroxisome prolifera-
tion is thought to be due, in part, to the increased peroxisomal
production of H2O2 via increased Acox1 activity (Varanasi et al.,
1996). Consequently, we also measured sod1 transcript and Sod1
activity as markers of oxidative stress (Fridovich, 1975), particu-
larly as sod1 has been identiﬁed as a gene target of PPAR and
responds to ﬁbrate treatment in rodents (Yoo et al., 1999; Wang
et al., 2010).Weobserved amodest increase in sod1mRNA levels on
day 10 at the pharmacological exposure concentration, which was
not, however, reﬂected by elevated enzyme activity, perhaps sug-
gesting alternative antioxidant pathways were activated, such as
catalase, glutathione peroxidase or glutathione-S-transferase (see
later) (Oruc et al., 2004).
The level of ppara transcription is believed to be auto-regulated
in mammals (Torra et al., 2002). Here ppara gene transcript levels
were signiﬁcantly increased after 4 days of exposure to CFA, but
not after 10 days, despite a number of other downstream target
gene transcripts remaining elevated. It may be the case that there
was a transient activation of transcription during the period of the
exposure study, with a peak in expression after 4 days and a subse-
quent return to basal expression by day 10. This hypothesis aligns
with a previous study in fathead minnow where it was found that
ppara gene expression was not signiﬁcantly elevated after 21 days
of exposure to 108.9mg/L CFA, despite an increase in activity of
Acox1 (Weston et al., 2009).
Therapeutically, in addition to reducing triglyceride synthe-
sis, ﬁbrates have been shown to alter lipoprotein metabolism and
cholesterol homeostasis in humans, via a number of PPAR reg-
ulated targets, including the apolipoproteins AI and AII (APOA1
and APOA2), lipoprotein lipase (LPL) (Staels et al., 1998), as well
as various enzymes involved in bile acid synthesis (cholesterol
catabolism) and transport in the liver (Kersten, 2008; Li andChiang,
2009). Interestingly, however, the Apoa1 gene in rodents is unre-
sponsive to PPAR activation (Vu-Dac et al., 1998). Here both lpl
and apoa1 mRNA levels were up-regulated in carp exposed to
CFA suggesting that the transcription of both genes is activated
by PPAR, as is the case in humans. This response pathway in
ﬁsh has not been fully investigated, however teleost apolipopro-
teins including apoa1 are known to be regulated by exposure to
oestradiol-17 and are thought to play a role in vitellogenesis
(Levi et al., 2009). The elevation of lpl mRNA levels at the envi-
ronmental CFA treatment concentration only is also curious. In a
previous study, exposure of rainbow trout to the related ﬁbrate
gemﬁbrozil resulted in elevated levels of the lpl gene transcript, but
not Lpl enzyme activity and therewas no evidence of the activation
of PPARs despite decreased plasma lipoprotein levels (Prindiville
et al., 2011). The pattern exhibited here with lpl (as well as cyp4
and acaa1mentioned above) mRNA, is the opposite to that of ppara
mRNA levels, perhaps reﬂecting indirect downstream activation
of lipoprotein/cholesterol regulation, negative feedback on ppara
transcription, or merely a reﬂection of the time-lag between recep-
tor and downstream pathway activation. More work is required to
fully understand the response shown here.
In mammals, it has been demonstrated that ﬁbrates disrupt
bile acid synthesis via the PPARmediated suppression of choles-
terol 7-hydroxylase (Cyp7a1) and sterol 27-hydroxylase (Cyp27a)
(Post et al., 2001). CYP7A1 catalyzes the ﬁrst and rate-limiting step
in the classical pathway, converting cholesterol into 7 hydroxyl
cholesterol; CYP27A mediates sterol side chain oxidation in the
classic pathway and catalyzes the ﬁrst two steps of the alterna-
tive pathway. The simultaneous inhibition of these enzymes after
long termﬁbrate treatment has been linked to imbalanced bile acid
and cholesterol secretions in humans (Pullinger et al., 2002). In our
study, cyp27a mRNA levels were reduced in carp after 4 days of
exposure to 20mg/L CFA, which is what would be expected based
on human function. However, after 10 days of exposure, cyp27a
transcript levelswere signiﬁcantly increased at both exposure con-
centrations; the opposite of what might be expected. Interestingly,
thepattern shownby the cyp27a transcriptmirrorsapoa1 transcript
levels, which would be expected to increase (Li and Chiang, 2009),
and could support an adaptive increase in bile acid synthesis as a
result of elevated cholesterol concentrations.
After 4 days of exposure to CFA, the overall in vivohepaticmRNA
level proﬁles in carp for the drug biotransformation and trans-
porter genes cyp2k, cyp3a, gsta, gstp,mdr1 (abcb1) andmrp2 (abcc2),
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were generally in agreement with data we previously generated
in an in vitro carp hepatocyte preparation (Corcoran et al., 2012).
All of the gene transcripts measured showed a signiﬁcant increase
in levels at one or both treatment concentration with the excep-
tion of gsta. Similarly, after 10 days transcription of all genes was
elevated at one or both treatment concentrations, with the excep-
tion of mdr1 which was signiﬁcantly down-regulated. This again
broadly mirrors data previously generated in our in vitro carp hep-
atocyte preparation after exposure to CFA (Corcoran et al., 2012)
and further supports a role for PPAR in the regulation of a number
of xenobiotic metabolizing enzymes in ﬁsh, as is hypothesized in
mammals.
As previously mentioned, Sod1 enzyme activity was unaltered
in our CFA-exposed animals. It may be that alternative oxidative
stress pathways were activated by exposure to CFA and the mea-
sured increased Acox1 activity. For example here gsta and gstp
transcript levels were elevated in a number of CFA-treated groups
comparedwithcontrols. InEuropeaneel (Anguilla anguilla) exposed
to the ﬁbrate gemﬁbrozil, there was little change in Gst activity,
but there was an increase in catalase activity (Lyssimachou et al.,
2014), another important mediator of cellular oxidative stress reg-
ulation. Taken together, this could suggest that activation of the
teleost PPAR results in hepatic oxidative stress necessitating the
activation of at least some cellular antioxidant defenses.
Collectively our data demonstrate that exposure of common
carp to the PPAR ligand CFA affects the level of transcripts of a
number of genes known to be regulated by PPAR inmammals, and
results in altered activity of the key peroxisomal enzyme Acox1, a
biomarker of exposure to PPs.
Determining a causal relationship between instantaneous mea-
sures of gene expression (at the time of termination) and the
resultant protein product is problematic, and the complexity of
the kinetics of synthesis and degradation adds to this difﬁculty
(Vogel and Marcotte, 2012). The paradigm used here, however,
was to examine selected nodal genes (Yu et al., 2007) believed to
be directly involved with the PPAR signaling pathway. Detect-
ing changes in the levels of transcript of these genes in relation to
those shown by control animals would strongly suggest that the
PPAR axis is under the inﬂuence of cloﬁbrate in the ﬁsh. How-
ever, although these ﬁndings support a role for PPAR in lipid
metabolism in ﬁsh, as is the case in mammals, a direct link in terms
of PPAR activation and altered biological function have yet to be
demonstrated.
Measured plasma concentrations in the pharmacological expo-
sure group were 6mg/L (approximately 30% of the measured water
concentration)which is at least 10 times lower than the therapeutic
plasma concentrations of CFA reported in humans (Regenthal et al.,
1999). As such the observed hepatic gene and enzyme responses
suggest that the carp PPAR and associated pathways appear rela-
tively sensitive to activation by CFA. Furthermore, several of these
transcriptional responses occur at a water concentration of 4g/L,
comparable with some of the concentrations reported in efﬂuents
discharged into the aquatic environment and a little below the
28 day growth NOEC of 10g/L reported for trout (Owen et al.,
2010). The plasma concentrations measured are in line with those
previously measured in rainbow trout plasma (Owen et al., 2010)
suggesting a similar level of bioavailability, however, the degree
and type of plasma protein binding remain unknown in ﬁsh. The
relatively similar plasma concentrations of CFA at the 4 and 10
day measurements indicate a low propensity for bioconcentration
in this tissue, unlike for gemﬁbrozil in goldﬁsh (Mimeault et al.,
2005). Moreover, effective depuration of CFA from the plasma, as
illustrated after transfer of exposed ﬁsh into clean water for 4 days,
would suggest a relatively short half-life for CFA in plasma in carp.
As previously highlighted, CFA is only one of a number of ﬁbrate
drugs to have been detected in the environment, for example
fenoﬁbrate, bezoﬁbrate and ciproﬁbrate have all been measured at
similar concentrations in surfacewaters (Runnalls et al., 2007). This
raises the possibility of additive effects due to strong similarities
in their mechanisms of action. Moreover, many other compounds
classed as PPs and acting via similar mechanisms are present in the
aquatic environment including herbicides, plasticizers and wood
pulp compounds, adding to the possible mixture effects of PPs on
these target endpoints in ﬁsh.
As a ﬁnal note, the study presented here suggests that PPAR
may be involved in regulating the transcription of a number of
important biotransformation genes in carp, in common with what
is known in mammals. This potentially extends the role of the
PPAR to not only a regulator of lipid homeostasis, but also a key
modulator of hepatic xenobiotic metabolism.
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